Navigation Links
drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
Date:2/6/2008

- Highest Revenues, Gross Margins and Net Income in Company History

BELLEVUE, Wash., Feb. 6 /PRNewswire-FirstCall/ -- drugstore.com, inc. (Nasdaq: DSCM), a leading online provider of health, beauty, vision, and pharmacy products, today announced its financial results for the fourth quarter and fiscal year ended December 30, 2007. The company reported quarterly net sales of $118.2 million and net income of $156,000, or $0.00 per share. The company achieved record gross margins in the fourth quarter of 24.6%, up 300 basis points year-over-year, and reported adjusted EBITDA of approximately $4.0 million. Adjusted EBITDA is a non-GAAP financial measure defined as earnings before interest, taxes, depreciation, and amortization of intangible assets and non-cash marketing expense, adjusted to exclude the impact of stock-based compensation expense.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070813/AQM043LOGO)

For the year, the company reported net sales of $445.7 million, a net loss of $9.0 million or $0.09 per share, and adjusted EBITDA of $9.1 million, reflecting an adjusted EBITDA improvement of approximately $6.8 million over fiscal year 2006. Additionally, the company reported operating cash flow of $7.8 million for 2007 compared to operating cash used of $1.1 million in the previous year.

"I am very pleased to announce that we reached GAAP profitability in the fourth quarter for the first time in company history," said Dawn Lepore, chief executive officer and chairman of the board of drugstore.com, inc. "During the quarter, we delivered record results across many of our key metrics including prestige beauty sales increasing 57% 1 3 2

Technology and content 1,185 1,064 5,252 4,119

General and administrative 110 107 423 443

$1,761 $1,540 $7,504 $6,040

SUPPLEMENTAL INFORMATION: Gross Profit and Gross Margin Information:

Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

(In thousands, unless

otherwise indicated)

Net sales $118,223 $108,598 $445,723 $415,777

Cost of sales 89,109 85,190 341,919 326,036

Gross profit $29,114 $23,408 $103,804 $89,741

Gross margin 24.6% 21.6% 23.3% 21.6%

SUPPLEMENTAL INFORMATION: Reconciliation of OTC net sales, cost of sales, gross profit, gross margin, variable order costs, and contribution margin to Core OTC net sales, cost of sales, gross profit, gross margin, variable order costs and contribution margin (See Note 3 below):

Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

(In thousands)

Over-the-Counter (OTC):

Net sales $65,870 $56,099 $234,282 $197,964

CNS 450 522 1,881 2,376

Core OTC net sales $65,420 $55,577 $232,401 $195,588

Cost of sales $45,378 $40,530 $164,469 $139,674

CNS 36 46 234 112

Core OTC cost of sales $45,342 $40,484 $164,235 $139,562

Gross profit 20,492 15,569 69,813 58,290

CNS 414 476 1,647 2,264

Core OTC gross profit $20,078 $15,093 $68,166 $56,026

Gross margin 31.1% 27.8% 29.8% 29.4%

CNS 92.0% 91.2% 87.6% 95.3%

Core OTC gross margin 30.7% 27.2% 29.3% 28.6%

Variable order costs $6,479 $5,456 $22,259 $18,650

CNS 144 161 607 711

Core OTC variable

order costs $6,335 $5,295 $21,652 $17,939

Contribution margin 14,013 10,113 47,554 39,640

CNS 270 315 1,040 1,553

Core OTC contribution

margin $13,743 $9,798 $46,514 $38,087

NOTE 3: Supplemental information related to the company's Core OTC net

sales, cost of sales, gross profit, gross margin, variable order

costs and contribution margin for the three and twelve months

ended December 30, 2007 and December 31, 2006 is presented for

informational purposes only and is not prepared in accordance with

generally accepted accounting principles. On December 31, 2005,

we entered into a fulfillment agreement with Weil Lifestyles, LLC,

resulting in Weil-related CNS net sales (which make up the

substantial majority of CNS net sales) being recorded on a net

basis after that date. All CNS sales were previously recorded on a

gross basis.

SUPPLEMENTAL INFORMATION: Segment Information:

Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

Net sales:

Over-the-Counter (OTC) $65,870 $56,099 $234,282 $197,964

Mail-order pharmacy 12,729 14,496 50,143 67,379

Local pick-up pharmacy 26,916 25,962 106,392 100,654

Vision 12,708 12,041 54,906 49,780

$118,223 $108,598 $445,723 $415,777

Cost of sales:

Over-the-Counter (OTC) $45,378 $40,530 $164,469 $139,674

Mail-order pharmacy 10,737 12,383 41,935 58,026

Local pick-up pharmacy 23,345 22,943 93,611 89,654

Vision 9,649 9,334 41,904 38,682

$89,109 $85,190 $341,919 $326,036

Gross profit:

Over-the-Counter (OTC) 20,492 15,569 69,813 58,290

Mail-order pharmacy 1,992 2,113 8,208 9,353

Local pick-up pharmacy 3,571 3,019 12,781 11,000

Vision 3,059 2,707 13,002 11,098

$29,114 $23,408 $103,804 $89,741

Gross margin:

Over-the-Counter (OTC) 31.1% 27.8% 29.8% 29.4%

Mail-order pharmacy 15.6% 14.6% 16.4% 13.9%

Local pick-up pharmacy 13.3% 11.6% 12.0% 10.9%

Vision 24.1% 22.5% 23.7% 22.3%

24.6% 21.6% 23.3% 21.6%

Variable order costs:

Over-the-Counter (OTC) $6,479 $5,456 $22,259 $18,650

Mail-order pharmacy 931 1,055 3,967 5,501

Local pick-up pharmacy 1,110 1,064 4,383 4,128

Vision 673 561 2,708 2,478

9,193 8,136 33,317 30,757

Contribution margin:

Over-the-Counter (OTC) $14,013 $10,113 $47,554 $39,640

Mail-order pharmacy 1,061 1,058 4,241 3,852

Local pick-up pharmacy 2,461 1,955 8,398 6,872

Vision 2,386 2,146 10,294 8,620

$19,921 $15,272 $70,487 $58,984

SUPPLEMENTAL INFORMATION: Reconciliation of Net Income (Loss) to Adjusted EBITDA (See Note 4 below):
Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

(In thousands, unless

otherwise indicated)

Net income (loss) $156 $(2,947) $(9,011) $(13,026)

Amortization of intangible

assets 244 468 1,234 2,060

Amortization of non-cash

marketing 573 573 2,290 2,290

Stock-based compensation 1,687 1,705 8,801 6,721

Depreciation 1,761 1,540 7,504 6,040

Interest income, net (410) (438) (1,675) (1,730)

Adjusted EBITDA $4,011 $901 $9,143 $2,355

NOTE 4: Supplemental information related to the company's adjusted EBITDA

for the three and twelve months ended December 30, 2007 and

December 31, 2006 is presented for informational purposes only and

is not prepared in accordance with generally accepted accounting

principles. Adjusted EBITDA is defined as earnings before taxes,

depreciation, and amortization of intangible assets and non-cash

marketing expense, adjusted to exclude the impact of stock-based

compensation expense.

SUPPLEMENTAL INFORMATION: Reconciliation of Forecasted Q1 2008

and FY 2008 Net Income (Loss) Range to Forecasted

Q1 2008 and FY 2008 Adjusted EBITDA Range

Range Calculated As: Three Months Ended Twelve Months Ended

March 30, 2008 December 28, 2008

(In thousands, unless

otherwise indicated) Range High Range Low Range High Range Low

Net income (loss) $(2,350) $(2,850) $3,000 $(1,000)

Amortization of

intangible assets 250 250 900 900

Amortization of

non-cash marketing 575 575 2,300 2,300

Stock-based compensation 2,100 2,100 7,300 7,300

Depreciation 2,225 2,225 10,500 10,500

Interest income, net (400) (400) (2,000) (2,000)

Adjusted EBITDA $2,400 $1,900 $22,000 $18,000

drugstore.com, inc.

Consolidated Balance Sheets

(in thousands, except share data)

December 30, December 31,

2007 2006

(unaudited) (audited)

ASSETS

Current assets:

Cash and cash equivalents $18,572 $13,393

Marketable securities 17,677 27,246

Accounts receivable, net of allowances 38,063 36,688

Inventories 31,501 26,469

Prepaid marketing expenses 2,327 2,290

Other current assets 3,605 2,615

Total current assets 111,745 108,701

Fixed assets, net 25,501 18,293

Other intangible assets, net 4,598 5,376

Goodwill 32,202 32,202

Prepaid marketing expenses and other 1,362 3,750

Total assets $175,408 $168,322

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $61,414 $57,507

Accrued compensation 4,657 4,841

Accrued marketing expenses 3,988 3,661

Other current liabilities 1,812 1,292

Current portion of long-term debt 3,179 3,949

Total current liabilities 75,050 71,250

Long-term debt, less current portion 1,221 1,839

Deferred income taxes 947 945

Other long-term liabilities 1,322 1,610

Stockholders' equity:

Common stock, $.0001 par value, stated at

amounts paid in:

Authorized shares - 250,000,000

Issued and outstanding shares -

96,296,687 and 94,335,027

as of December 30, 2007 and

December 31, 2006, respectively 856,193 843,026

Accumulated other comprehensive income (loss) 27 (7)

Accumulated deficit (759,352) (750,341)

Total stockholders' equity 96,868 92,678

Total liabilities and stockholders' equity $175,408 $168,322

drugstore.com, inc.

Consolidated Statements of Cash Flows

(in thousands)

Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

(unaudited) (unaudited) (audited)

Operating activities:

Net income (loss) $156 $(2,947) $(9,011) $(13,026)

Adjustments to reconcile

net loss to net cash

provided by (used in)

operating activities:

Depreciation 1,761 1,540 7,504 6,040

Amortization of

marketing and sales

agreements 573 573 2,290 2,290

Amortization of

intangible assets 244 468 1,234 2,060

Stock-based

compensation 1,687 1,705 8,801 6,721

Other, net 2 - 14 24

Changes in:

Accounts receivable (2,759) (1,178) (1,375) (2,474)

Inventories (9,001) (4,513) (5,032) (3,001)

Prepaid marketing

expenses and other 62 (483) (929) 5

Accounts payable,

accrued expenses and

other liabilities 8,021 4,731 4,282 278

Net cash provided by

(used in) operating

activities 746 (104) 7,778 (1,083)

Investing activities:

Purchases of marketable

securities (11,004) (4,822) (27,544) (22,853)

Sales and maturities of

marketable securities 21,316 4,700 37,141 21,775

Purchases of fixed

assets (3,466) (2,020) (14,249) (7,564)

Purchases of intangible

assets - - (456) -

Net cash provided by

(used in) investing

activities 6,846 (2,142) (5,108) (8,642)

Financing activities:

Proceeds from exercise of

stock options and

employee stock purchase

plan 985 1,319 4,366 2,716

Proceeds from line of

credit, term loan and

asset financings 3,700 1,325 4,000 2,325

Principal payments on

line of credit, capital

lease and term loan

obligations (3,667) (497) (5,857) (2,214)

Net cash provided by

financing activities 1,018 2,147 2,509 2,827

Net increase

(decrease) in

cash and cash

equivalents 8,610 (99) 5,179 (6,898)

Cash and cash

equivalents,

beginning of period 9,962 13,492 13,393 20,291

Cash and cash

equivalents, end of

period $18,572 $13,393 $18,572 $13,393

year-over-year, gross margins up over 300 basis points year-over-year, and core OTC [1] contribution margin dollars up 40% year-over-year. Our core OTC business grew 18% year-over-year, in-line with ecommerce trends, but below our expectations due to increased marketing costs in paid search and portals."

"Throughout 2008, we expect to accelerate our full year top line revenue growth by: increasing sales in each one of our business segments, driving OTC sales by 20% year-over-year and increasing prestige beauty sales more than 40% year-over-year. In the first quarter of 2008, we are making targeted investments in a number of our profitability initiatives including pricing and sourcing to further expand margins. We will start to see the benefits of these investments in the second quarter and we expect to double full year adjusted EBITDA and to exit the year with gross margins above 26% and adjusted EBITDA margins between 5-6%," concluded Ms. Lepore.

GAAP net income for the fourth quarter of 2007 was $156,000, or $0.00 per share, compared to a net loss of $2.9 million, or $0.03 per share, for the fourth quarter of 2006. The fourth quarter in both 2007 and 2006 included $1.7 million in non-cash stock-based compensation expense. GAAP net loss for the fiscal year of 2007 was $9.0 million or $0.09 per share, compared to a net loss of $13.0 million, or $0.14 per share, for the fiscal year of 2006. The fiscal year losses include $8.8 million and $6.7 million, in non-cash stock- based compensation expense for 2007 and 2006, respectively.

Outlook for First Quarter and Fiscal Year 2008

For fiscal year 2008, the company is targeting net sales in the range of $498.0 million to $512.0 million, net income in the range of $(1.0) million to $3.0 million, and adjusted EBITDA in the range of $18.0 million to $22.0 million.

For the first quarter of 2008, the company is targeting net sales in the range of $118.0 million to $122.0 million, net loss in the range of $2.9 million to $2.4 million, and adjusted EBITDA in the range of $1.9 million to $2.4 million. First quarter adjusted EBITDA guidance includes a $1.3 million investment in consulting services associated with profitability initiatives, which will result in improved margins throughout the remainder of 2008.

Financial and Operational Highlights for the Fourth Quarter of 2007

(All comparisons are made to the fourth quarter of 2006)

Key Financial Highlights:

-- Gross margins for the quarter increased 300 basis points to a record

high of 24.6%. For the year, gross margins improved 170 basis points

to 23.3%.

-- Total contribution margin dollars increased by over 30% for the quarter

and for the year improved by 20%.

-- Total orders grew by 9% to 1.6 million, while contribution margin

dollars per order grew almost 20% to approximately $13. For the year,

total orders increased by 10%, while contribution margin dollars per

order grew to approximately $12.

-- Cash, cash equivalents and marketable securities were $36.2 million at

year end.

Net Sales Summary:

-- Core OTC [1] revenues grew by approximately 18% to $65.4 million in the

quarter and increased by 19% to $232.4 million for the year.OTC net

sales grew by over 17% to $65.9 million. For the year, OTC net sales

grew by over 18% to $234.3 million.

-- Vision net sales grew approximately 6% to $12.7 million and for the

year increased over 10% to $54.9 million.

-- Local pick-up pharmacy net sales were up approximately 4% to

$26.9 million and for the year increased by approximately 6% to

$106.4 million.

-- Mail-order pharmacy net sales were down to $12.7 million. For the

year, mail order pharmacy net sales decreased 26% while contribution

margins dollars increased 10%.

-- Average net sales per order were $75 for the quarter and year. Average

net sales per order increased to $59 for OTC, grew 10% to $102 for

vision, and were $107 for local pick-up pharmacy and $165 for

mail-order pharmacy. For the year, average net sales per order

increased to $57 for OTC, grew 10% to $99 for vision, and were $106 for

local pick-up pharmacy and $159 for mail-order pharmacy.

-- Net sales from repeat customers [2] represented 80% of net sales for

the quarter and 82% of net sales for the year.

Key Customer Milestones:

-- New customers grew to 398,000.

-- We have now served nearly 10 million customers since inception.

-- The number of active customers [3] was 2.5 million.

1. Core OTC net sales is a non-GAAP financial measure that excludes from

OTC net sales the company's Custom Nutrition Services ("CNS") net

sales. CNS sales are generated by sales of customized vitamins through

the company's CNS subsidiary. Prior to December 31, 2005, all CNS

sales were recognized on a gross basis, net of promotional discounts,

cancellations, rebates and returns allowances. Under the terms of the

company's December 31, 2005 fulfillment agreement with Weil Lifestyle,

LLC (Weil), the company recognizes on a net basis the revenue

associated with the fulfillment of customized vitamins sold through its

fulfillment agreement with Weil. A reconciliation of OTC net sales to

core OTC net sales is included in the financial data accompanying this

press release.

2. Net sales from repeat customers exclude Weil-related CNS net sales and

reflect only the activity of customers making purchases through the Web

sites of drugstore.com and its subsidiaries.

3. Active customer base reflects those customers who have purchased at

least once within the last 12 months. Both the active customer base (a

trailing 12-month number) and average annual spend per active customer

exclude net sales and orders generated by the company's CNS fulfillment

relationship with Weil, and reflect only the activity of customers

making purchases through the Web sites of drugstore.com and its

subsidiaries.

Conference Call

Investors, analysts, and other interested parties are invited to join the drugstore.com, inc. quarterly conference call on February 6, 2008 at 5:00 p.m. ET (2:00 p.m. PT). To participate, callers should dial 800-257-2182 (international callers should dial 303-262-2140) five minutes beforehand. Investors may also listen to the conference call live at http://investor.drugstore.com/, by clicking on the "audio" hyperlink. A replay of the call will be available through Friday, February 8, 2008 by dialing 800-405-2236 (enter pass code 11106968#) or internationally at 303-590-3000 (enter pass code 11106968#) beginning two hours after completion of the call.

Non-GAAP Measures

To supplement the consolidated financial statements presented in accordance with GAAP, drugstore.com, inc. uses the non-GAAP measure of adjusted EBITDA, defined as earnings before interest, taxes, depreciation, and amortization of intangible assets and non-cash marketing expenses, adjusted to exclude the impact of stock-based compensation expense. This non-GAAP measure is provided to enhance the user's overall understanding of the company's current financial performance. Management believes that adjusted EBITDA, as defined, provides useful information to the company and to investors by excluding certain items that may not be indicative of the company's core operating results. In addition, because drugstore.com, inc. has historically provided adjusted EBITDA measures to investors, management believes that including adjusted EBITDA measures provides consistency in the company's financial reporting. However, adjusted EBITDA should not be considered in isolation, or as a substitute for, or as superior to, net income/loss, cash flows, or other consolidated income/loss or cash flow data prepared in accordance with GAAP, or as a measure of the company's profitability or liquidity. Although adjusted EBITDA is frequently used as a measure of operating performance, it is not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. Net income/loss is the closest financial measure prepared by the company in accordance with GAAP in terms of comparability to adjusted EBITDA. A reconciliation of adjusted EBITDA to net income/loss is included with the financial statements attached to this release.

drugstore.com, inc. also uses non-GAAP measures in which CNS sales are excluded from OTC segment sales data. This non-GAAP measure is provided to enhance the user's overall understanding of the company's financial performance in the OTC segment. Management believes that these reporting metrics provide useful information to the company and to investors by excluding certain items that may not be indicative of the company's core operating results in the OTC segment. By excluding CNS sales from OTC sales data, the company can more effectively assess the buying behavior of, and the company's financial performance with respect to, its own core OTC customers (those customers making nonprescription purchases through Web sites owned by drugstore.com, inc. and its subsidiaries). However, these non-GAAP measures should not be considered in isolation, or as a substitute for, or as superior to, OTC segment sales data prepared in accordance with GAAP, or as a measure of the company's overall performance in the OTC segment. OTC segment sales measures are the closest financial measures prepared by the company in accordance with GAAP in terms of comparability to OTC segment sales measures that exclude CNS sales.

About drugstore.com, inc.

drugstore.com, inc. (NASDAQ: DSCM) is a leading online provider of health, beauty, vision, and pharmacy products. Our portfolio of brands includes: drugstore.com(TM), Beauty.com(TM) and VisionDirect.com(TM). All are accessible from http://www.drugstore.com and provide a convenient, private, and informative shopping experience while offering a wide assortment of more than 30,000 products at competitive prices.

The drugstore.com pharmacy is certified by the National Association of Boards of Pharmacy (NABP) as a Verified Internet Pharmacy Practice Site (VIPPS) and operates in compliance with federal and state laws and regulations in the United States.

The financial results contained in this press release are preliminary and unaudited. In addition, this press release contains forward-looking statements regarding future events or the future financial and operational performance of drugstore.com, inc. Words such as "target," "expect," "believe," "may," "will," "focus," "continue," "would," "should," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements are based on current expectations, are not guarantees of future performance and involve assumptions, risks, and uncertainties. Actual performance may differ materially from those contained or implied in such forward-looking statements. Risks and uncertainties that could lead to such differences could include, among other things: effects of changes in the economy, changes in consumer spending, fluctuations in the stock market, changes affecting the Internet, online retailing and advertising, difficulties establishing our brand, and building a critical mass of customers, the unpredictability of future revenues and expenses and potential fluctuations in revenues and operating results, risks related to business combinations and strategic alliances, possible tax liabilities relating to the collection of sales tax, consumer trends, the level of competition, seasonality, the timing and success of expansion efforts, changes in senior management, risks related to systems interruptions, possible governmental regulation and the ability to manage a growing business. Additional information regarding factors that potentially could affect the business, financial condition and operating results of drugstore.com, inc. is included in the company's periodic filings with the SEC on Forms 10-K, 10-Q and 8-K. drugstore.com, inc. expressly disclaims any intent or obligation to update any forward-looking statement, except as otherwise specifically stated by it.

Contact:

Investor Relations:

Brinlea Johnson or Chris Danne

415-489-2189

brinlea@blueshirtgroup.com or chris@blueshirtgroup.com

drugstore.com, inc.

Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

Net sales $118,223 $108,598 $445,723 $415,777

Costs and expenses:(1)(2)

Cost of sales 89,109 85,190 341,919 326,036

Fulfillment and

order processing 11,999 10,704 44,200 41,099

Marketing and sales 8,942 7,919 32,370 29,735

Technology and content 4,388 4,199 18,258 16,190

General and administrative 3,795 3,503 18,428 15,413

Amortization of

intangible assets 244 468 1,234 2,060

Total costs and

expenses 118,477 111,983 456,409 430,533

Operating loss (254) (3,385) (10,686) (14,756)

Interest income, net 410 438 1,675 1,730

Net income (loss) $156 $(2,947) $(9,011) $(13,026)

Basic net income

(loss) per share $0.00 $(0.03) $(0.09) $(0.14)

Diluted net income

(loss) per share $0.00 $(0.03) $(0.09) $(0.14)

Weighted average shares

used in computation of:

Basic net income

(loss) per share 96,229,531 94,027,508 95,350,046 93,405,405

Diluted net income

(loss) per share 97,894,513 94,027,508 95,350,046 93,405,405

(1) Set forth below are the amounts of stock-based compensation by

operating function recorded in the Statements of Operations:

Fulfillment and order

processing $138 $196 $784 $835

Marketing and sales 303 233 1,381 1,058

Technology and content 289 225 1,224 1,071

General and administrative 957 1,051 5,412 3,757

$1,687 $1,705 $8,801 $6,721

(2) Set forth below are the amounts of depreciation by operating function

recorded in the Statements of Operations:

Fulfillment and order

processing $466 $368 $1,826 $1,476

Marketing and sales -
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com and Revolution Health Group Announce Breakthrough Deal
4. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
5. Joint Commission International Achieves Accreditation from ISQua
6. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
7. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. LMS integrated obstetrics solution achieves general availability
11. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology: